Ziprasidone Associated With Increased Risk of Hyperglycemia, Diabetes

"The U.S. Food and Drug Administration (FDA) and Pfizer have notified healthcare professionals by letter of revisions to the warnings section of drug labeling for ziprasidone (Geodon), according to an alert sent today from MedWatch, the FDA's safety information and adverse event reporting system. The warning refers to the increased risk of hyperglycemia and diabetes in patients treated with ziprasidone and other atypical antipsychotics."